1160707-44-7

Basic information

• Product Name: 1-(4-(3-Chloropropoxy)-5-methoxy-2-nitrophenyl)ethanone
• Synonyms: 1-(4-(3-Chloropropoxy)-5-methoxy-2-nitrophenyl)ethanone
• CAS NO: 1160707-44-7
• Molecular Weight: 287.7
• EINECS: -0
• Mol File: 1160707-44-7.mol
• Article Data: 47

Chemical Properties

• CAS DataBase Reference: 1-(4-(3-Chloropropoxy)-5-methoxy-2-nitrophenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-(3-Chloropropoxy)-5-methoxy-2-nitrophenyl)ethanone(1160707-44-7)
• EPA Substance Registry System: 1-(4-(3-Chloropropoxy)-5-methoxy-2-nitrophenyl)ethanone(1160707-44-7)

Safety Data

• Hazardous Substances Data: 1160707-44-7(Hazardous Substances Data)

Usage

General Description

1-(4-(3-Chloropropoxy)-5-methoxy-2-nitrophenyl)ethanone is a chemical compound with the molecular formula C13H14ClNO5. It is a yellow solid with a molecular weight of 295.71 g/mol. 1-(4-(3-Chloropropoxy)-5-methoxy-2-nitrophenyl)ethanone is often used in research and development, as well as in the pharmaceutical industry for its potential therapeutic properties. It is derived from the phenyl ethanone class of organic compounds and contains a nitro group, a chloro group, and a methoxy group, making it a versatile molecule for various applications in chemistry and medicine. The specific properties and uses of this chemical compound may vary depending on the context and application.

Upstream product

• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 58113-30-7 4-(3-chloropropoxy)-3-methoxyacetophenone 
• 3245-49-6 1-[4-(3-bromopropoxy)-3-methoxyphenyl]ethanone 

Downstream Products

• 1219937-96-8 1-[5-methoxy-4-(3-morpholin-4-yl-propoxy)-2-nitro-phenyl]-ethanone 
• 1394165-16-2 N-(3-fluoro-4-((6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-1-(2-chlorophenyl)-4-oxo-1,4-dihydrocinnoline-3-carboxamide 
• 1436418-02-8 N-(3-fluoro-4-((6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-1-(2-(trifluoromethyl)phenyl)-4-oxo-1,4-dihydrocinnoline-3-carboxamide 
• 1394165-23-1 N-(3-fluoro-4-((6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-1-(3-fluorophenyl)-4-oxo-1,4-dihydrocinnoline-3-carboxamide 
• 1394165-20-8 N-(3-fluoro-4-((6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-1-(3-(trifluoromethyl)phenyl)-4-oxo-1,4-dihydrocinnoline-3-carboxamide 
• 1394165-24-2 N-(3-fluoro-4-((6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-1-(4-chlorophenyl)-4-oxo-1,4-dihydrocinnoline-3-carboxamide 
• 1394165-17-3 N-(3-fluoro-4-((6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-1-(4-bromophenyl)-4-oxo-1,4-dihydrocinnoline-3-carboxamide 
• 1394165-41-3 N-(3-fluoro-4-((6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-1-(2,4-dichlorophenyl)-4-oxo-1,4-dihydrocinnoline-3-carboxamide 
• 1394165-43-5 N-(3-fluoro-4-((6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-1-(2,6-dichlorophenyl)-4-oxo-1,4-dihydrocinnoline-3-carboxamide 
• 1436418-50-6 1-(2,4-dimethylphenyl)-N-(3-fluoro-4-(6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinolin-4-yloxy)phenyl)-4-oxo-1,4-dihydrocinnoline-3-carboxamide 
• 1394165-28-6 N-(3-fluoro-4-((6-methoxy-7-(3-(4-methylpiperidin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-1-(2-fluorophenyl)-4-oxo-1,4-dihydrocinnoline-3-carboxamide 
• 1436418-03-9 1-(2-bromophenyl)-N-(3-fluoro-4-(6-methoxy-7-(3-(4-methylpiperidin-1-yl)propoxy)quinolin-4-yloxy)phenyl)-4-oxo-1,4-dihydrocinnoline-3-carboxamide 
• 1436418-04-0 N-(3-fluoro-4-(6-methoxy-7-(3-(4-methylpiperidin-1-yl)propoxy)quinolin-4-yloxy)phenyl)-4-oxo-1-(3-(trifluoromethyl)phenyl)-1,4-dihydrocinnoline-3-carboxamide 
• 1436418-05-1 N-(3-fluoro-4-((6-methoxy-7-(3-(4-methylpiperidin-1-yl)propoxy)quinolin-4-yl)oxy)phenyl)-1-(4-fluorophenyl)-4-oxo-1,4-dihydrocinnoline-3-carboxamide 

Relevant articles and documents

Design and optimization of novel 4-(2-fluorophenoxy)quinoline derivatives bearing a hydrazone moiety as c-Met kinase inhibitors

A series of 4-(2-fluorophenoxy)quinoline derivatives containing an acylhydrazone moiety were designed, synthesized and evaluated for their in vitro biological activities against c-Met kinase and five cancer cell lines (A549, H460, HT-29, MKN-45, and U87MG). Most compounds showed weak to excellent antiproliferative activity. The most promising analog, 40 (c-Met IC50 Combining double low line 1.86 nM), displayed 1.3-, 6.8-, 1.5-, 3.5-fold increase against HT-29, H460, A549 and U87MG cell lines, respectively, compared with Foretinib. An analysis of structure-activity relationships revealed that an acylhydrazone scaffold with an unsubstituted sp2 hybridized carbon adjacent to the 4-CF3 phenyl ring is favorable for antitumor activity.

New Synthetic Process for Bosutinib

A new and improved synthetic route to bosutinib is described on a hectogram scale. The key step is the intramolecular cyclization of a 3-(2-aminophenyl)-3-oxopropanenitrile with N,N-dimethylformamide dimethyl acetal to form the 3-cyano-4-hydroxyquinoline ring of 7-(3-chloropropoxy)-6-methoxy-4-oxo-1,4-dihydroquinoline-3-carbonitrile. A practical synthetic method to 2,4-dichloro-5-methoxyaniline is also established. Bosutinib is obtained in 18.0% yield over nine steps from acetovanillone with 98.9% purity (HPLC).

Novel substituted pyrazolo [1, 5-a] pyrimidine compound and preparation method and application thereof

The invention provides a novel substituted pyrazolo [1, 5-a]pyrimidine compound and a preparation method and application thereof, and particularly relates to a pyrazolo [1, 5-a]pyrimidine-containing quinoline derivative shown as a general formula (I) and pharmaceutically acceptable salts thereof, and substituent groups X, Ar and A have meanings given in the specification. The invention also relates to a compound represented by the general formula (I), wherein the compound has a strong c-Met kinase inhibition effect. The invention also relates to application of the compound and the pharmaceutically acceptable salt thereof in preparation of drugs for treating and/or preventing diseases caused by abnormal high expression of c-Met kinase, especially application in preparation of drugs for treating and/or preventing cancers.

1,3-disubstituted urea and thiourea derivative and application thereof

The invention discloses a 1,3-disubstituted urea and thiourea derivative and application thereof in the field of pharmaceutical chemistry. A structural formula of the derivative is as shown in the specification, and the derivative gives play to an antitumor function through inhibition of tyrosine protein kinase activity, wherein main tyrosine protein kinase inhibited by the derivative includes c-Met, IGF-1R, Src, c-Kit and the like. The derivative can be used for preparation of medicines for preventing or treating hyperplastic diseases, lung cancers, liver cancers, gastric cancers, colon cancers and breast cancers.